Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc (Nasdaq: NBIX) is a neuroscience-focused biopharmaceutical company whose news flow centers on clinical data, product performance and pipeline progress in movement disorders, neuropsychiatry, endocrinology and metabolic disease. The company regularly issues updates on its flagship VMAT2 inhibitor INGREZZA (valbenazine) for tardive dyskinesia and chorea associated with Huntington’s disease, including head-to-head pharmacologic studies, long-term efficacy analyses and peer-reviewed publications.
NBIX news commonly features clinical trial readouts across its pipeline. Recent releases have covered Phase 3 and Phase 4 data for INGREZZA in tardive dyskinesia and Huntington’s disease chorea, a Phase 3 study of valbenazine in dyskinetic cerebral palsy, and Phase 2 results for investigational compounds such as NBI-1070770 in major depressive disorder. Investors and clinicians can also follow updates on late-stage programs including osavampator for major depressive disorder and direclidine for schizophrenia and bipolar mania, as well as next-generation VMAT2 inhibitors and CRF-based therapies for metabolic diseases like obesity.
Another major theme in Neurocrine Biosciences news is financial and corporate reporting. The company announces quarterly net product sales for INGREZZA and CRENESSITY, provides guidance ranges for research and development and selling, general and administrative expenses, and discusses its R&D strategy at events such as its annual R&D Day and healthcare investor conferences. Management presentations at large industry meetings, including the J.P. Morgan Healthcare Conference and other investor conferences, are also highlighted in press releases.
This NBIX news page aggregates these updates so readers can quickly review earnings announcements, clinical milestones, R&D strategy briefings, investor conference appearances and key scientific publications related to Neurocrine Biosciences. For anyone tracking developments in tardive dyskinesia, Huntington’s disease chorea, classic congenital adrenal hyperplasia, neuropsychiatric disorders or emerging CRF-based metabolic therapies, the news stream provides a concise view of the company’s ongoing activities and disclosures.
Neurocrine Biosciences (Nasdaq: NBIX) said members of its management team will present at two investor conferences: a Jefferies Global Healthcare Conference fireside chat on November 18, 2025 at 12:00 PM GMT (7:00 AM ET) in London, and a Piper Sandler 37th Annual Healthcare Conference fireside chat on December 2, 2025 at 9:30 AM ET in New York.
Both presentations will be live webcast via the company's Investors page at www.neurocrine.com. Replays will be posted about one hour after each event and will be archived for approximately one month.
Neurocrine Biosciences (Nasdaq: NBIX) announced top-line results from a Phase 2 signal-seeking study of NBI-1070770 in adults with major depressive disorder (MDD) on Nov 10, 2025.
The study enrolled 73 adults with inadequate response to at least one antidepressant. The compound did not meet the primary endpoint versus placebo. NBI-1070770 was reported to be generally well tolerated. Company management said it will continue data analyses to determine next steps.
Neurocrine Biosciences (Nasdaq: NBIX) reported third-quarter 2025 results on Oct 28, 2025: Total net product sales $790M (+28% YoY, +16% sequential).
INGREZZA sales were $687M (+12% YoY, +10% sequential) with record new patient starts; CRENESSITY sales were $98M with 540 new patient enrollment start forms and ~80% reimbursement coverage.
Third-quarter GAAP net income was $209.5M (EPS $2.04); non-GAAP net income was $222.1M (EPS $2.17). Cash and marketable securities totaled about $2.11B. Company reaffirmed full-year INGREZZA guidance of $2.5B–$2.55B and provided 2025 R&D and SG&A ranges.
Neurocrine Biosciences (NASDAQ: NBIX) presented a post‑hoc analysis from the Phase 3 KINECT 4 study showing that continuous treatment with INGREZZA 40 mg once daily produced rapid, sustained, clinically meaningful improvements in tardive dyskinesia (TD) over 48 weeks.
Key outcomes: mean AIMS total score change exceeded the minimally clinically important difference at all post‑baseline visits; 90% (18/20) of participants who completed 48 weeks on continuous 40 mg reached ≥50% AIMS improvement; patients who reduced from 80 mg to 40 mg showed similar benefit. Safety was consistent with the known profile, with most adverse events mild/moderate and the most common being sleepiness and tiredness. Findings were presented October 15–18, 2025 at the American Psychiatric Nurses Association conference.
Neurocrine Biosciences (NASDAQ: NBIX) will release its third quarter 2025 financial results and host a conference call and webcast on October 28, 2025. The press release is scheduled for 1:00 p.m. PT / 4:00 p.m. ET, followed by the conference call at 1:30 p.m. PT / 4:30 p.m. ET.
Dial-in numbers: Domestic 800-274-8461, International 203-518-9814 with Conference ID: NBIX. The webcast will be available on the company's Investors page at neurocrine.com, with a replay posted about one hour after the event and archived for ~one month.
Neurocrine Biosciences (Nasdaq: NBIX) announced on October 6, 2025 the appointment of Mike Sibley as Senior Vice President and General Manager of its Neuropsychiatry franchise.
Sibley will lead sales and marketing strategy for Neurocrine's neuropsychiatry products, including the INGREZZA franchise. He brings more than 20 years of commercial biopharma experience and joins after a nine-year tenure at Sanofi, most recently as General Manager for US Dermatology. Prior roles include positions at Galderma, J.P. Morgan Chase & Co., and Johnson & Johnson. Sibley holds a Bachelor of Arts in Economics from the University of Massachusetts, Amherst.
Neurocrine Biosciences (Nasdaq: NBIX) presented three-year open-label KINECT-HD2 data showing once-daily INGREZZA (valbenazine) produced early and sustained reductions in Huntington's disease chorea with an established long-term safety profile.
Key results: 154 adults treated up to 156 weeks; mean UHDRS Total Maximal Chorea improvement by Week 2 was -3.4±0.3 (n=146); PGI-C responders rose from 34.5% at Week 2 to 77.8% at Week 156. TEAEs were consistent with known safety: 97.4% reported ≥1 TEAE; most common were falls (42.9%), somnolence (25.3%), fatigue (21.4%); discontinuations due to TEAEs were 15.6%.
Neurocrine Biosciences (NASDAQ:NBIX) announced new post-hoc analysis data from their Phase 4 KINECT-PRO™ study of INGREZZA® (valbenazine) for tardive dyskinesia (TD) treatment. The study showed that 57.8% of patients (26 of 45) achieved symptomatic remission at Week 24, with success rates of 58.3% at 40mg, 44.4% at 60mg, and 62.5% at 80mg doses.
The analysis demonstrated significant improvements in patient-reported outcomes among those achieving remission, including enhanced quality of life and reduced disease burden. Notably, patients showed substantial improvements across multiple measures: the Tardive Dyskinesia Impact Scale (TDIS™), Sheehan Disability Scale (SDS), and EuroQoL Visual Analog Scale (EQ-VAS). The safety profile remained consistent with previous findings, with no new concerns identified.
[ "High remission rate of 57.8% achieved at Week 24 across different dosages", "Significant improvements in patient-reported outcomes and quality of life metrics", "Earlier achievement of TD symptom remission compared to previous studies", "Consistent safety profile with no new concerns identified" ]Neurocrine Biosciences (Nasdaq: NBIX) announced positive results from its Phase 2 SAVITRI™ study of osavampator (NBI-1065845) for major depressive disorder (MDD). The study demonstrated statistically significant improvements in depression severity at both Day 28 and Day 56 with 1 mg daily oral dosing.
The trial, involving 183 adults, tested two doses (1 mg and 3 mg) against placebo. The 1 mg dose achieved the primary endpoint with significant MADRS score reduction and showed superior results in treatment response and remission rates. Osavampator, a first-in-class selective AMPA-PAM, was well-tolerated with no serious adverse events, with headache and nasopharyngitis being the most common side effects.
Neurocrine Biosciences (Nasdaq: NBIX) will present new data from its Phase 2 SAVITRI study of osavampator at Psych Congress 2025. The study investigates osavampator as an adjunctive treatment for adults with major depressive disorder (MDD) who have inadequate response to oral antidepressants.
Following positive top-line results, the company initiated a Phase 3 registrational program in January 2025, comprising five active enrolling studies. The company will present multiple posters, with two selected as finalists for Psych Congress Poster Awards, focusing on osavampator's clinical improvements in depression severity and its mechanism as a selective AMPA-PAM.